What does a FibroSure result showing a fibrosis score of 0.47 (stage F1‑F2), necroinflammatory activity score of 0.23 (grade A0‑A1), and alpha‑2‑macroglobulin level of 302 mg/dL indicate?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

FibroSure Result Interpretation

Your FibroSure results indicate mild-to-moderate liver fibrosis (F1-F2 stage) with minimal inflammatory activity (A0-A1 grade), though the elevated alpha-2-macroglobulin level suggests the test may be overestimating fibrosis severity and should be interpreted cautiously.

Understanding Your Scores

Fibrosis Assessment

  • Fibrosis Score: 0.47 (reference range 0.00-0.21)
    • This score places you in the F1-F2 stage, indicating mild-to-moderate fibrosis
    • F1 = portal fibrosis without septa (early scarring)
    • F2 = portal fibrosis with few septa (moderate scarring extending beyond portal areas)
    • This is considered "significant fibrosis" but not advanced disease 1, 2

Inflammatory Activity

  • Necroinflammatory Activity Score: 0.23 (reference range 0.00-0.17)
    • Grade A0-A1 indicates minimal to no active inflammation
    • This suggests relatively quiet disease activity despite the fibrosis 3

Alpha-2-Macroglobulin Elevation

  • Level: 302 mg/dL (reference range 110-276 mg/dL)
    • This is mildly elevated and is one of the key components driving your FibroSure score
    • Alpha-2-macroglobulin increases with fibrosis but can also be elevated in other conditions 4, 5

Clinical Significance

What This Means for You

The F1-F2 stage represents early-to-moderate liver disease that requires monitoring but typically does not indicate cirrhosis or advanced fibrosis (F3-F4). According to current guidelines, patients with F2 fibrosis should be evaluated for the underlying cause of liver disease and monitored over time 2.

Important Caveats About FibroSure Accuracy

The diagnostic accuracy of FibroSure has important limitations:

  • For distinguishing F0-F1 from F2-F4 fibrosis, FibroSure shows moderate accuracy with sensitivity of 80% and specificity of 63% 4
  • False positives occur in approximately 21% of cases where the test suggests significant fibrosis but biopsy shows mild disease 6
  • The test performs better at excluding advanced fibrosis (F3-F4) than at precisely staging intermediate levels like F1-F2 1, 3

Why Your Alpha-2-Macroglobulin Matters

The elevated alpha-2-macroglobulin is driving your fibrosis score upward. This protein can be elevated due to:

  • Actual liver fibrosis 5
  • Inflammatory conditions unrelated to the liver
  • Hemolysis (if blood sample was handled improperly)
  • Other metabolic conditions

This means your actual fibrosis stage could be lower than F1-F2, potentially just F0-F1 (minimal or no fibrosis).

Recommended Next Steps

Immediate Actions

  1. Identify the underlying liver disease cause

    • Viral hepatitis testing (HBV, HCV)
    • Metabolic liver disease evaluation (NAFLD/MASLD screening)
    • Alcohol use assessment
    • Autoimmune and cholestatic liver disease workup
  2. Consider additional noninvasive testing for confirmation 2:

    • FIB-4 score (calculated from age, AST, ALT, platelets) - this is recommended as first-line assessment and may provide more reliable staging
    • Liver stiffness measurement via FibroScan/elastography if available
    • These alternative tests can help confirm or refute the FibroSure findings
  3. Repeat testing in 6-12 months to assess for progression, as single time-point measurements have limitations

When to Consider Liver Biopsy

Liver biopsy should be considered if 3:

  • There is discordance between different noninvasive tests
  • The diagnosis remains uncertain and would change management
  • You have symptoms or laboratory findings suggesting more advanced disease than the FibroSure indicates

Surveillance Recommendations

For F1-F2 fibrosis 2:

  • No routine hepatocellular carcinoma screening is needed (this starts at F3-F4/cirrhosis)
  • No variceal screening is needed (this is for cirrhosis)
  • Monitor for disease progression with repeat noninvasive testing annually or as clinically indicated
  • Address modifiable risk factors (weight loss if NAFLD, alcohol cessation, treatment of viral hepatitis)

Key Takeaway

Your results suggest mild-to-moderate fibrosis without significant inflammation, but given the test's moderate accuracy at this stage and your elevated alpha-2-macroglobulin, correlation with additional noninvasive tests (particularly FIB-4) and clinical context is essential before making definitive management decisions. The good news is that F1-F2 fibrosis is potentially reversible with treatment of the underlying cause and does not carry the same risks as advanced fibrosis or cirrhosis 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.